DNA hypomethylation and human diseases

被引:602
作者
Wilson, Ann S.
Power, Barbara E.
Molloy, Peter L.
机构
[1] Preventat Hlth Natl Res Flagship, N Ryde, NSW 1670, Australia
[2] CSIRO, Mol & Hlth Technol, N Ryde, NSW 1670, Australia
[3] CSIRO, Mol & Hlth Technol, Parkville, Vic 3052, Australia
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2007年 / 1775卷 / 01期
关键词
DNA hypomethylation; global demethylation; cancer; biomarker; transposable element; repeat sequence;
D O I
10.1016/j.bbcan.2006.08.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Changes in human DNA methylation patterns are an important feature of cancer development and progression and a potential role in other conditions such as atherosclerosis and autoimmune diseases (e.g., multiple sclerosis and lupus) is being recognised. The cancer genome is frequently characterised by hypermethylation of specific genes concurrently with an overall decrease in the level of 5 methyl cytosine. This hypomethylation of the genome largely affects the intergenic and intronic regions of the DNA, particularly repeat sequences and transposable elements, and is believed to result in chromosomal instability and increased mutation events. This review examines our understanding of the patterns of cancer-associated hypomethylation, and how recent advances in understanding of chromatin biology may help elucidate the mechanisms underlying repeat sequence demethylation. It also considers how global demethylation of repeat sequences including transposable elements and the site-specific hypomethylation of certain genes might contribute to the deleterious effects that ultimately result in the initiation and progression of cancer and other diseases. The use of hypomethylation of interspersed repeat sequences and genes as potential biomarkers in the early detection of tumors and their prognostic use in monitoring disease progression are also examined. Crown Copyright (c) 2006 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:138 / 162
页数:25
相关论文
共 210 条
[1]   Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer [J].
Agoston, AT ;
Argani, P ;
Yegnasubramanian, S ;
De Marzo, AM ;
Ansari-Lari, MA ;
Hicks, JL ;
Davidson, NE ;
Nelson, WG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (18) :18302-18310
[2]   Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy [J].
Akcakanat, A ;
Kanda, T ;
Tanabe, T ;
Komukai, S ;
Yajima, K ;
Nakagawa, S ;
Ohashi, M ;
Hatakeyama, K .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (01) :123-128
[3]   NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer [J].
Akcakanat, A ;
Kanda, T ;
Koyama, Y ;
Watanabe, M ;
Kimura, E ;
Yoshida, Y ;
Komukai, S ;
Nakagawa, S ;
Odani, S ;
Fujii, H ;
Hatakeyama, K .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 54 (01) :95-100
[4]  
[Anonymous], P NATL ACAD SCI USA
[5]   Methylation in the core-promoter region of the chondromodulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3 [J].
Aoyama, T ;
Okamoto, T ;
Nagayama, S ;
Nishijo, K ;
Ishibe, T ;
Yasura, K ;
Nakayama, T ;
Nakamura, T ;
Toguchida, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (27) :28789-28797
[6]   X-chromosome inactivation: Counting, choice and initiation [J].
Avner, P ;
Heard, E .
NATURE REVIEWS GENETICS, 2001, 2 (01) :59-67
[7]  
Bacher CP, 2006, NAT CELL BIOL, V8, P293, DOI 10.1038/ncb1365
[8]   Reversing histone methylation [J].
Bannister, AJ ;
Kouzarides, T .
NATURE, 2005, 436 (7054) :1103-1106
[9]   The relationship between hypomethylation and CpG island methylation in colorectal neoplasia [J].
Bariol, C ;
Suter, C ;
Cheong, K ;
Ku, SL ;
Meagher, A ;
Hawkins, N ;
Ward, R .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04) :1361-1371
[10]   Aberrant methylation of gene promoters in cancer - Concepts, misconcepts, and promise [J].
Baylin, SB ;
Belinsky, SA ;
Herman, JG .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (18) :1460-1461